Publicaciones en colaboración con investigadores/as de Hospital de Santa Maria (14)

2024

  1. Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387

2023

  1. Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands

    International Journal of Epidemiology, Vol. 52, Núm. 4, pp. E241-E252

2022

  1. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

2020

  1. Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium

    Blood Cancer Journal, Vol. 10, Núm. 7

  2. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Blood Cancer Journal, Vol. 10, Núm. 10

  3. Major bleeding predictors in patients with left atrial appendage closure: The iberian registry ii

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-11

2019

  1. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial

    Arthritis and Rheumatology, Vol. 71, Núm. 10, pp. 1616-1625

2017

  1. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

    International Journal of Molecular Sciences, Vol. 18, Núm. 4

2016

  1. An initial investigation of abnormal bodily phenomena in subjects at ultra high risk for psychosis: Their prevalence and clinical implications

    Comprehensive Psychiatry, Vol. 66, pp. 39-45

  2. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

  3. Prevalence and implications of Truman symptoms in subjects at ultra high risk for psychosis

    Psychiatry Research, Vol. 238, pp. 270-276

2015

  1. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

    British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354

2013

  1. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma

    Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 247-255

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051